© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 16, 1316-1321,
August 16, 2000
© 2000 Oxford University Press
Prospective Study of Cyclin D1 Overexpression in Barrett's Esophagus: Association With Increased Risk of Adenocarcinoma
Affiliations of authors: K. Bani-Hani, I. G. Martin, Department of Surgery, Leeds General Infirmary, U.K., L. J. Hardie, J. A. Briggs, C. P. Wild (Molecular Epidemiology Unit, Epidemiology and Health Services Research, School of Medicine), N. Mapstone (Department of Pathology), Algernon Firth Building, Leeds; D. Forman, Cancer Epidemiology Group, Epidemiology and Health Services Research, School of Medicine, University of Leeds.
Correspondence to: Christopher P. Wild, Ph.D., Molecular Epidemiology Unit, Epidemiology and Health Services Research, School of Medicine, Algernon Firth Building, Leeds LS2 9JT, U.K. (e-mail: c.p.wild{at}leeds.ac.uk).
Background: Esophageal adenocarcinoma commonly arises from a precancerous condition, Barrett's esophagus, in which the normal squamous epithelium is replaced by a columnar cell-lined epithelium. Genetic alterations occurring in this process could serve as biomarkers for the risk of malignant progression, improve surveillance, and contribute to early diagnosis. We examined two potential biomarkers, cyclin D1 and p53, in a prospective cohort of Barrett's esophagus patients. Methods: A total of 307 patients were enrolled in an endoscopic surveillance cohort, and esophageal biopsy specimens were collected at each endoscopy. Incident cases of adenocarcinoma were matched to control patients within the cohort by duration of follow-up, age, sex, and length of columnar cell-lined epithelium at recruitment. Biopsy specimens were analyzed for cyclin D1 and p53 protein levels by immunohistochemistry. Statistical tests were two-sided. Results: A total of 12 cases of adenocarcinoma occurred within the follow-up period, and tumor biopsy specimens from 11 cases stained positive for cyclin D1. Biopsy specimens from eight of these patients taken at recruitment also stained positive for cyclin D1. A case–control analysis of biopsy specimens obtained at recruitment revealed a statistically significantly increased risk of progression to adenocarcinoma in Barrett's esophagus patients whose biopsy specimens were cyclin D1 positive (odds ratio [OR] = 6.85; 95% confidence interval [CI] = 1.57–29.91; P = .0106) but not in patients whose biopsy specimens were p53 positive (OR = 2.99; 95% CI = 0.57–15.76; P = .197). Conclusions: Cyclin D1-positive staining could be a useful biomarker in identifying Barrett's esophagus patients at high risk of esophageal adenocarcinoma. Given the complexity of genetic alterations in the natural history of this cancer, additional biomarkers will be required to increase the sensitivity and specificity of molecular diagnosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. di Pietro, C. J. Peters, and R. C. Fitzgerald Clinical puzzle: Barrett's oesophagus Dis. Model. Mech., July 1, 2008; 1(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Risques, T. L. Vaughan, X. Li, R. D. Odze, P. L. Blount, K. Ayub, J. L. Gallaher, B. J. Reid, and P. S. Rabinovitch Leukocyte Telomere Length Predicts Cancer Risk in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2649 - 2655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Aggarwal, M. D. Lessie, D. I. Lin, L. Pontano, A. B. Gladden, B. Nuskey, A. Goradia, M. A. Wasik, A. J.P. Klein-Szanto, A. K. Rustgi, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication Genes & Dev., November 15, 2007; 21(22): 2908 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zagorowicz and J. Jankowski Molecular changes in the progression of Barrett's oesophagus Postgrad. Med. J., August 1, 2007; 83(982): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fitzgerald Molecular Tools for Predicting the Behavior of Barrett's Esophagus Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 133 - 138. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Izzo, T.-T. Wu, X. Wu, J. Ensor, R. Luthra, J. Pan, A. Correa, S. G. Swisher, C. K.S. Chao, W. N. Hittelman, et al. Cyclin D1 Guanine/Adenine 870 Polymorphism With Altered Protein Expression Is Associated With Genomic Instability and Aggressive Clinical Biology of Esophageal Adenocarcinoma J. Clin. Oncol., February 20, 2007; 25(6): 698 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lao-Sirieix, L. Lovat, and R. C. Fitzgerald Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance Clin. Cancer Res., January 15, 2007; 13(2): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L Preston and J A Jankowski Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full! Gut, October 1, 2006; 55(10): 1377 - 1379. [Full Text] [PDF]
|
|
|
|
|
|
L Murray, A Sedo, M Scott, D McManus, J M Sloan, L J Hardie, D Forman, and C P Wild TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort Gut, October 1, 2006; 55(10): 1390 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Finley, B. J. Reid, R. D. Odze, C. A. Sanchez, P. Galipeau, X. Li, S. G. Self, K. A. Gollahon, P. L. Blount, and P. S. Rabinovitch Chromosomal Instability in Barrett's Esophagus Is Related to Telomere Shortening. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1451 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Wang, T.-T. Wu, E. Resetkova, H. Wang, A. M. Correa, W. L. Hofstetter, S. G. Swisher, J. A. Ajani, A. Rashid, S. R. Hamilton, et al. Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association with Poor Outcome Clin. Cancer Res., August 1, 2006; 12(15): 4598 - 4604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Keswani, A. Noffsinger, I. Waxman, and M. Bissonnette Clinical Use of p53 in Barrett's Esophagus. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1243 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schottenfeld and J. Beebe-Dimmer Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin, March 1, 2006; 56(2): 69 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lao-Sirieix, A. Roy, C. Worrall, S. L. Vowler, S. Gardiner, and R. C. Fitzgerald Effect of Acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 288 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Cook, C. P. Wild, and D. Forman A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett's Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease Am. J. Epidemiol., December 1, 2005; 162(11): 1050 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Bani-Hani, N. M. Almasri, Y. S. Khader, F. M. Sheyab, and H. N. Karam Combined Evaluation of Expressions of Cyclin E and p53 Proteins as Prognostic Factors for Patients with Gastric Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1447 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A I Sarela, C S Verbeke, C Pring, and P J Guillou Is symptom control the correct end point for proton pump inhibitor treatment in Barrett's oesophagus? Gut, September 1, 2004; 53(9): 1387 - 1388. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. McManus, A. Olaru, and S. J. Meltzer Biomarkers of Esophageal Adenocarcinoma and Barrett's Esophagus Cancer Res., March 1, 2004; 64(5): 1561 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Gammon, M. B. Terry, N. Arber, W.-H. Chow, H. A. Risch, T. L. Vaughan, J. B. Schoenberg, S. T. Mayne, J. L. Stanford, R. Dubrow, et al. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 34 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N J Trudgill, S K Suvarna, J A Royds, and S A Riley Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction Mol. Pathol., December 1, 2003; 56(6): 313 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lu, A. B. Gladden, and J. A. Diehl An Alternatively Spliced Cyclin D1 Isoform, Cyclin D1b, Is a Nuclear Oncogene Cancer Res., November 1, 2003; 63(21): 7056 - 7061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Miller, J. R. Moy, L. Lin, M. Schipper, D. Normolle, D. E. Brenner, M. D. Iannettoni, M. B. Orringer, and D. G. Beer Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia Clin. Cancer Res., October 15, 2003; 9(13): 4819 - 4825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K K Basu and J S de Caestecker Surveillance in Barrett's oesophagus: a personal view Postgrad. Med. J., May 1, 2002; 78(919): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kagei, M. Hosokawa, H. Shirato, T. Kusumi, Y. Shimizu, A. Watanabe, and M. Ueda Efficacy of Intense Screening and Treatment for Synchronous Second Primary Cancers in Patients with Esophageal Cancer Jpn. J. Clin. Oncol., April 1, 2002; 32(4): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M R Alison, T Hunt, and S J Forbes Minichromosome maintenance (MCM) proteins may be pre-cancer markers Gut, March 1, 2002; 50(3): 290 - 291. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wong, T. G. Paulson, L. J. Prevo, P. C. Galipeau, G. Longton, P. L. Blount, and B. J. Reid p16INK4a Lesions Are Common, Early Abnormalities that Undergo Clonal Expansion in Barrett's Metaplastic Epithelium Cancer Res., November 1, 2001; 61(22): 8284 - 8289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen and C. S. Yang Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Eksteen, J. A Jankowski, C. P. Wild, D. Forman, R. A Carr, I. L P Beales, R J Playford, A C B Wicks, and C E Macdonald Surveillance for Barrett's oesophagus BMJ, May 5, 2001; 322(7294): 1124 - 1124. [Full Text]
|
|
|
|
 |
|
 J. L. Weissfeld Cyclin D1 and Esophageal Adenocarcinoma Risk: How Good Does a Marker Have to Be? J Natl Cancer Inst, August 16, 2000; 92(16): 1282 - 1283. [Full Text] [PDF]
|
|